A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Solid Malignant Tumor Clinical Trial

Official title:

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02223247
• Other study ID #: 3V2640-CLIN-002
• Status: Completed
• Phase: Phase 1
• First received: August 18, 2014
• Last updated: August 11, 2017
• Start date: November 2013
• Est. completion date: June 2017

Study information

• Verified date: August 2017
• Source: 3V Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This first in human phase 1 study of TVB-2640 is being conducted in patients with advanced stage solid malignant tumors. This research is being done to find out how safe and useful TVB-2640 is for patients who have received previous cancer therapy, and for whom no therapy exists that would be curative or might provide significant benefit. TVB-2640 belongs to a class of drugs called fatty acid synthase inhibitors (FASN inhibitors). This means that they interfere with the body's (and the tumor's) ability to use a substance called fatty acid synthase (FASN). Research has shown that some tumors appear to need FASN to keep growing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria Include:

• Patient has histologically- or cytologically- confirmed metastatic or advanced-stage solid malignant tumor that is refractory to standard therapy and for whom no therapy exists that would be curative or might provide significant benefit and therefore for whom experimental therapy is a reasonable option.

• Patient experienced progressive disease during or following or was intolerant of their most recent treatment regimen.

• Patient is male or female aged =18 years.

• Patient has an ECOG performance status of 0 (fully active, able to carry out all pre-disease activities without restriction) or 1 (unable to perform physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), as assessed on C1D1, before the first dose of TVB 2640.

• Patient has adequate renal function (creatinine =1.5 times the upper limit of normal [ULN]) or a glomerular filtration rate (GFR) of =50 mL/min.

• Patient has adequate hepatic function,

• Patient has adequate bone marrow function

• Patient has no significant ischemic heart disease or myocardial infarction (MI) within 6 months before the first dose of TVB 2640 and currently has adequate cardiac function

For the Monotherapy Expansion Cohorts of the Study ONLY:

• Patient has a specific tumor-type and histology, as designated by the Sponsor based on nonclinical and clinical data obtained prior to enrollment in the Expansion Cohort.

• Patient has measurable disease, as determined by the Investigator using RECIST, version 1.1 (1).

For the Combination Cohorts ONLY:

• In addition to meeting monotherapy criteria above, the commercially-available anticancer agent of interest being investigated in combination with TVB-2640, administered according to the dose regimen in the prescribing information, is deemed appropriate for the patient's disease and clinical status.

Exclusion Criteria Include:

• Patient is unable to swallow oral medications or has impairment of GI function or GI disease that may significantly alter drug absorption

• Patient has uncontrolled or severe intercurrent medical condition (including uncontrolled brain metastases).

• Patient underwent major surgery within 4 weeks before the first dose of TVB 2640 or received cancer-directed therapy or an investigational drug or device within 4 weeks (6 weeks for mitomycin C and nitrosoureas) or 5 half-lives of that agent (whichever is shorter) before the first dose of TVB 2640.

• If female, patient is pregnant or breast-feeding.

• Patient has evidence of a serious active infection

• Patient has a history of other malignancy treated with curative intent within the previous 5 years with the exception of adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.

Related Conditions & MeSH terms

• Neoplasms
• Solid Malignant Tumor

Intervention

Drug:
• TVB-2640

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
3V Biosciences, Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the maximum tolerated dose (MTD) based on toxicity analysis.	Toxicity will be monitored according to NCI - Common Toxicity Criteria for Adverse Events version (4.03). Patients receiving at least one dose of drug.	1.5 years
Primary	To determine the incidence and nature of dose-limiting toxicities (DLTs) of TVB-2640.		Days 1 to 21 of cycle 1 for monotherapy cohort(s); Days 1 to 28 of cycle 1 for combination with anti-cancer agent cohort(s)
Secondary	Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03).		Up to 28 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first.
Secondary	Pharmacokinetic parameters of TVB-2640 (including total exposure, maximum and minimum serum concentration, clearance, volume of distribution at steady state)	Cmax, Cmin, Tmax, AUC and Half-life of TVB-2640	At Cycle Day 1, 2, 8, 15, (and 22 for combination cohorts) then the first day of subsequent cycles until discontinuation.
Secondary	Tumor response per RECIST 1.1		Measured every 6 weeks for 21 day cycles or every 8 weeks for 28 day cycles for the duration of study treatment, estimated to be less than one year